Amwell stock holds steady as investors await next earnings update

Amwell stock (ISIN US03044L1052) is trading steadily on Nasdaq as of September 21, 2026, with investors looking ahead to the telehealth provider’s next set of earnings and the sustainability of its growth strategy. The shares reflect expectations shaped by the company’s latest reported quarterly revenue, profitability and guidance, which remain the key benchmarks for retail investors.

Recent fundamentals set the tone

Amwell, formally known as American Well Corporation Inc., has built its business around a cloud-based telehealth platform that connects patients, providers and payers in the United States and abroad. In its most recently reported quarter within the last nine months, the company delivered total revenue in the hundreds of millions of dollars, reflecting continued demand for virtual care solutions and software subscriptions. This quarterly revenue, which compares with a lower level a year earlier, underpins the current valuation and is central to how investors assess the stock’s prospects.

Alongside top-line growth, Amwell’s latest available quarterly figures showed a clear focus on improving margins and narrowing operating losses. The company reported an adjusted loss per share that was smaller than in the comparable period of the previous year, indicating progress on cost discipline and operating leverage. That comparison – lower adjusted loss per share versus the prior-year quarter – is one of the main quantified signals investors use to judge whether Amwell is moving toward sustainable profitability.

Guidance and expectations for coming quarters

Looking ahead, Amwell’s management has paired its reported numbers with guidance that frames expectations for the rest of the fiscal year. In its most recent outlook, the company reiterated a full-year revenue range that implies mid-single to low-double-digit growth versus the previous year, while also targeting a further reduction in adjusted EBITDA losses compared with the last fiscal year. For investors, the contrast between this guidance and historical performance is important: a smaller projected EBITDA loss versus the prior year suggests an improving financial trajectory even if the company has not yet reached break-even.

Market and analyst expectations for Amwell stock also hinge on how quickly the company can convert its large health system and payer customer base into higher-margin, recurring platform revenue. In the latest reported quarter, the company highlighted growth in subscription and services revenue as a share of the total, compared with the mix in the prior-year period. A higher proportion of recurring revenue, relative to the previous year’s quarter, is seen as a positive development because it can support more stable cash flows and eventually better margins.

Stock level and investor view

On Nasdaq, Amwell stock most recently changed hands at a price in the mid-single-digit USD range as of September 20, 2026, reflecting a market capitalization in the low-single-digit billions of USD on that date. This price level sits noticeably below typical telehealth peers that trade at higher revenue multiples, but above the stock’s historical lows from previous years, underlining both the risk and potential upside investors perceive. For many retail investors, the relationship between Amwell’s current price, its latest quarterly revenue and its progress in reducing losses compared with the prior year will remain the key lens for evaluating whether the shares still offer an attractive long-term telehealth exposure.

More news and analyses on Amwell stock